Cargando…

Cardiovascular Risk Assessment in Rheumatoid Arthritis: Accelerated Atherosclerosis, New Biomarkers, and the Effects of Biological Therapy

Rheumatoid arthritis (RA), one of the most common of the chronic inflammatory autoimmune diseases (CIADs), is recognized as an independent cardiovascular risk factor. Traditional risk factors such as smoking, arterial hypertension, dyslipidemia, insulin resistance, and obesity are frequently found i...

Descripción completa

Detalles Bibliográficos
Autores principales: Popescu, Diana, Rezus, Elena, Badescu, Minerva Codruta, Dima, Nicoleta, Seritean Isac, Petronela Nicoleta, Dragoi, Ioan-Teodor, Rezus, Ciprian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965162/
https://www.ncbi.nlm.nih.gov/pubmed/36836675
http://dx.doi.org/10.3390/life13020319
_version_ 1784896689335697408
author Popescu, Diana
Rezus, Elena
Badescu, Minerva Codruta
Dima, Nicoleta
Seritean Isac, Petronela Nicoleta
Dragoi, Ioan-Teodor
Rezus, Ciprian
author_facet Popescu, Diana
Rezus, Elena
Badescu, Minerva Codruta
Dima, Nicoleta
Seritean Isac, Petronela Nicoleta
Dragoi, Ioan-Teodor
Rezus, Ciprian
author_sort Popescu, Diana
collection PubMed
description Rheumatoid arthritis (RA), one of the most common of the chronic inflammatory autoimmune diseases (CIADs), is recognized as an independent cardiovascular risk factor. Traditional risk factors such as smoking, arterial hypertension, dyslipidemia, insulin resistance, and obesity are frequently found in RA. Given the increased risk of mortality and morbidity associated with cardiovascular disease (CVD) in RA patients, screening for risk factors is important. Moreover, there is a need to identify potential predictors of subclinical atherosclerosis. Recent studies have shown that markers such as serum homocysteine, asymmetric dimethylarginine, or carotid intima–media thickness (cIMT) are correlated with cardiovascular risk. Although RA presents a cardiovascular risk comparable to that of diabetes, it is not managed as well in terms of acute cardiovascular events. The introduction of biological therapy has opened new perspectives in the understanding of this pathology, confirming the involvement and importance of the inflammatory markers, cytokines, and the immune system. In addition to effects in inducing remission and slowing disease progression, most biologics have demonstrated efficacy in reducing the risk of major cardiovascular events. Some studies have also been conducted in patients without RA, with similar results. However, early detection of atherosclerosis and the use of targeted therapies are the cornerstone for reducing cardiovascular risk in RA patients.
format Online
Article
Text
id pubmed-9965162
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99651622023-02-26 Cardiovascular Risk Assessment in Rheumatoid Arthritis: Accelerated Atherosclerosis, New Biomarkers, and the Effects of Biological Therapy Popescu, Diana Rezus, Elena Badescu, Minerva Codruta Dima, Nicoleta Seritean Isac, Petronela Nicoleta Dragoi, Ioan-Teodor Rezus, Ciprian Life (Basel) Review Rheumatoid arthritis (RA), one of the most common of the chronic inflammatory autoimmune diseases (CIADs), is recognized as an independent cardiovascular risk factor. Traditional risk factors such as smoking, arterial hypertension, dyslipidemia, insulin resistance, and obesity are frequently found in RA. Given the increased risk of mortality and morbidity associated with cardiovascular disease (CVD) in RA patients, screening for risk factors is important. Moreover, there is a need to identify potential predictors of subclinical atherosclerosis. Recent studies have shown that markers such as serum homocysteine, asymmetric dimethylarginine, or carotid intima–media thickness (cIMT) are correlated with cardiovascular risk. Although RA presents a cardiovascular risk comparable to that of diabetes, it is not managed as well in terms of acute cardiovascular events. The introduction of biological therapy has opened new perspectives in the understanding of this pathology, confirming the involvement and importance of the inflammatory markers, cytokines, and the immune system. In addition to effects in inducing remission and slowing disease progression, most biologics have demonstrated efficacy in reducing the risk of major cardiovascular events. Some studies have also been conducted in patients without RA, with similar results. However, early detection of atherosclerosis and the use of targeted therapies are the cornerstone for reducing cardiovascular risk in RA patients. MDPI 2023-01-23 /pmc/articles/PMC9965162/ /pubmed/36836675 http://dx.doi.org/10.3390/life13020319 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Popescu, Diana
Rezus, Elena
Badescu, Minerva Codruta
Dima, Nicoleta
Seritean Isac, Petronela Nicoleta
Dragoi, Ioan-Teodor
Rezus, Ciprian
Cardiovascular Risk Assessment in Rheumatoid Arthritis: Accelerated Atherosclerosis, New Biomarkers, and the Effects of Biological Therapy
title Cardiovascular Risk Assessment in Rheumatoid Arthritis: Accelerated Atherosclerosis, New Biomarkers, and the Effects of Biological Therapy
title_full Cardiovascular Risk Assessment in Rheumatoid Arthritis: Accelerated Atherosclerosis, New Biomarkers, and the Effects of Biological Therapy
title_fullStr Cardiovascular Risk Assessment in Rheumatoid Arthritis: Accelerated Atherosclerosis, New Biomarkers, and the Effects of Biological Therapy
title_full_unstemmed Cardiovascular Risk Assessment in Rheumatoid Arthritis: Accelerated Atherosclerosis, New Biomarkers, and the Effects of Biological Therapy
title_short Cardiovascular Risk Assessment in Rheumatoid Arthritis: Accelerated Atherosclerosis, New Biomarkers, and the Effects of Biological Therapy
title_sort cardiovascular risk assessment in rheumatoid arthritis: accelerated atherosclerosis, new biomarkers, and the effects of biological therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965162/
https://www.ncbi.nlm.nih.gov/pubmed/36836675
http://dx.doi.org/10.3390/life13020319
work_keys_str_mv AT popescudiana cardiovascularriskassessmentinrheumatoidarthritisacceleratedatherosclerosisnewbiomarkersandtheeffectsofbiologicaltherapy
AT rezuselena cardiovascularriskassessmentinrheumatoidarthritisacceleratedatherosclerosisnewbiomarkersandtheeffectsofbiologicaltherapy
AT badescuminervacodruta cardiovascularriskassessmentinrheumatoidarthritisacceleratedatherosclerosisnewbiomarkersandtheeffectsofbiologicaltherapy
AT dimanicoleta cardiovascularriskassessmentinrheumatoidarthritisacceleratedatherosclerosisnewbiomarkersandtheeffectsofbiologicaltherapy
AT seriteanisacpetronelanicoleta cardiovascularriskassessmentinrheumatoidarthritisacceleratedatherosclerosisnewbiomarkersandtheeffectsofbiologicaltherapy
AT dragoiioanteodor cardiovascularriskassessmentinrheumatoidarthritisacceleratedatherosclerosisnewbiomarkersandtheeffectsofbiologicaltherapy
AT rezusciprian cardiovascularriskassessmentinrheumatoidarthritisacceleratedatherosclerosisnewbiomarkersandtheeffectsofbiologicaltherapy